Status and phase
Conditions
Treatments
About
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
Full description
This study will assess the safety, tolerability and weight loss associated with XEN-101 in obese men and women.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
33 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Dennis Kim, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal